Search
News
Aligos Q2 2026 earnings: Licensing revenue narrows the quarterly loss
Aligos Therapeutics (ALGS) reported Q2 2026 revenue of $27.8 million, compared with $1.0 million a year earlier, as licensing revenue offset a roughly 72% increase in R&D spending. Net loss narrowed to $1.5 million, or $0.14 per diluted share, from $15.9 million, or $1.53 per share. Cash, equivalents and investments were $30.4 million at June 30, excluding a $25 million upfront payment received in July. The company’s funding runway extends through Q4 2026, while B-SUPREME topline data are expected in late Q3 2027.
TradingKey
Thu, Aug 6
Prime Medicine Q2 2026 Earnings: Lower Costs Narrow the Net Loss
Prime Medicine’s Q2 2026 earnings showed collaboration revenue of $1.154 million, up about 3.5% year over year, while net loss narrowed to $42.1 million and EPS improved to -$0.24 from -$0.41. R&D and G&A spending declined after workforce, facility, compensation, and legal-cost reductions. The company ended June with $108.8 million in cash, investments, and restricted cash, which it expects to fund operations into 2027 as PM577a enters Phase 1/2 startup, PM647 approaches a regulatory filing, and PM359 advances toward a planned BLA submission.
TradingKey
Thu, Aug 6
ALX Oncology Q2 2026 Results: Lower R&D Spending Narrows Net Loss
ALX Oncology’s Q2 2026 results showed a GAAP net loss of $18.0 million, or $0.13 per share, compared with $25.9 million, or $0.49 per share, a year earlier. R&D expense fell to $13.1 million as legacy-trial costs declined, while cash, cash equivalents and investments reached $153.4 million at June 30. The company says this liquidity can fund planned operations through the first half of 2028. Investors are now focused on ALX2004 safety data in the second half of 2026 and the ASPEN-09-Breast topline readout expected in mid-2027.
TradingKey
Thu, Aug 6
Tejon Ranch Q2 2026 Earnings: Land Sale Helps Restore Profitability
Tejon Ranch’s Q2 2026 revenue increased about 72% year over year to $14.3 million, while diluted EPS improved to $0.10 from a $0.06 loss. Net income attributable to common stockholders reached $2.6 million, and adjusted EBITDA rose 46% to $8.4 million. The quarter benefited from a $6.9 million land sale tied to the Dedeaux Properties joint venture, lower corporate expenses, and growth in multifamily, mineral resources, and ranch operations. Investors should monitor land-sale timing, Terra Vista leasing, development spending, and farming yield uncertainty after unfavorable bloom-period rainfall.
TradingKey
Thu, Aug 6
Aemetis Q2 2026 earnings: Tax credits restore operating profit
Aemetis reported Q2 2026 revenue of $62.7 million, up 20% year over year, while diluted loss per share narrowed to $0.13 from $0.41. Gross profit reached $13.5 million and operating income turned positive at $5.8 million, helped by $8.6 million of Section 45Z tax-credit revenue, lower delivered corn costs, and higher Dairy RNG production. Adjusted EBITDA improved to $9.7 million, but $15.2 million of total interest expense left the company with a $9.4 million net loss. Cash ended the quarter at $1.0 million, keeping financing and liquidity central to the outlook.
TradingKey
Thu, Aug 6
Globalstar Q2 2026 earnings: Higher costs drive an operating loss
Globalstar (GSAT) reported Q2 2026 revenue of $64.8 million, down about 4% year over year, and diluted EPS of -$0.23 versus $0.13. Adjusted EBITDA declined 27% to $26.0 million as higher network, XCOM development and transaction-related costs outweighed Commercial IoT growth and higher equipment sales. The prior-year quarter also included $6.6 million of out-of-period wholesale capacity revenue. For the first half, adjusted free cash flow fell to $43.5 million while capital expenditures reached $208.3 million amid continued satellite and ground-network investment.
TradingKey
Thu, Aug 6
Establishment Labs Q2 2026 earnings: U.S. growth lifts gross margin
Establishment Labs (NASDAQ: ESTA) reported Q2 2026 revenue of $67.5 million, up 31.7% year over year, while diluted net loss per share narrowed to $0.39 from $0.57. Gross margin increased to 70.6% from 68.8% as higher-margin U.S. and minimally invasive sales improved the mix, and adjusted EBITDA turned positive at $3.7 million. Motiva USA revenue reached $24.7 million, and the company raised full-year revenue guidance to $269 million-$271 million. GAAP losses, negative first-half operating cash flow, and debt remain important areas to monitor.
TradingKey
Thu, Aug 6
Hertz Q2 2026 Earnings: Pricing Drives 10% Revenue Growth
Hertz Q2 2026 revenue rose 10% year over year to $2.396 billion as RPD increased 9% despite a 1% smaller average fleet and essentially flat transaction days. GAAP net income reached $64 million, or $0.05 per diluted share, while adjusted Corporate EBITDA improved by $63 million to $81 million. Pricing outpaced daily operating-cost growth, but recalls affected nearly 15,000 vehicles and reduced adjusted EBITDA by about $30 million. Hertz expects full-year RPU above $1,500 and net depreciation per unit of $300 or less.
TradingKey
Thu, Aug 6
Marcus & Millichap Q2 2026 Earnings: Revenue Growth Restores Profitability
Marcus & Millichap’s preliminary Q2 2026 earnings showed revenue rising 17.8% year over year to $202.9 million, while diluted EPS improved to $0.10 from a $0.28 loss. Net income reached $3.9 million versus an $11.0 million loss, and adjusted EBITDA increased to $12.1 million from $1.5 million. Brokerage commissions and financing fees both advanced, led by faster growth in larger transactions, although a higher commission mix lifted cost of services to 62.4% of revenue. Management expects rate, inflation and bid-ask spread pressures to persist through 2026.
TradingKey
Thu, Aug 6
CION Q2 2026 Earnings: Unrealized Gains Lift NAV and EPS
CION Investment Corporation’s Q2 2026 total investment income fell 4.7% year over year to $49.8 million, while earnings per share rose to $0.62 from $0.52. Net investment income declined to $14.2 million, or $0.29 per share, but $34.8 million of unrealized gains lifted quarterly earnings and helped NAV per share increase 3.5% sequentially to $13.57. The funded portfolio contracted by $90 million, non-accrual exposure improved, and net debt-to-equity declined to 1.52x as CION continued deleveraging and expanded its authorized repurchase program to $130 million.
TradingKey
Thu, Aug 6
USA TODAY Co. Q2 2026 Earnings: Cost Cuts Support Profit Despite Lower Revenue
USA TODAY Co. (NYSE: TDAY) reported Q2 2026 revenue of $536.3 million, down 8.3% year over year, while diluted EPS fell to $0.06 from $0.52. The EPS comparison was distorted by an $87.5 million tax benefit in the prior-year quarter; pretax income improved to $14.5 million from a $9.1 million loss. Free cash flow rose approximately 11% to $19.6 million, and management reiterated its 2026 outlook as digital subscriptions grew but total digital and print revenue remained lower.
TradingKey
Thu, Aug 6
Ralph Lauren Fiscal Q1 2027 Earnings: Revenue Rises 14% as Margins Expand
Ralph Lauren’s fiscal Q1 2027 revenue rose 14% to $2.0 billion, while GAAP diluted EPS increased 22% to $4.28. Adjusted operating margin expanded 170 basis points to 18.7%, supported by 15% growth in average unit retail, full-price demand, and favorable channel and geographic mix despite tariff and product-cost pressure. Asia led the regions with 24% reported revenue growth, while North America increased 13%. The company raised its full-year constant-currency revenue outlook to 5%-6% and now expects 60-80 basis points of constant-currency operating-margin expansion.
TradingKey
Thu, Aug 6
Insight Enterprises Q2 2026 Earnings: AI-Led Growth Expands Margins
Insight Enterprises’ Q2 2026 net sales rose 15% year over year to $2.40 billion, while GAAP diluted EPS climbed 76% to $2.57. Gross profit increased 18% to $521.6 million and gross margin widened 60 basis points to 21.7%, supported by AI-related demand across cloud, infrastructure, and services. Adjusted diluted EPS advanced 44% to $3.86, although operating activities used $12.2 million of cash. North America drove operating profit growth, while EMEA remained a pressure point. The company also raised its full-year guidance.
TradingKey
Thu, Aug 6
Delcath Q2 2026 Earnings: Revenue Rises While Clinical Spending Pressures EBITDA
Delcath Systems’ Q2 2026 revenue rose about 21% year over year to $29.1 million, led by $27.1 million from HEPZATO KIT, while diluted EPS remained $0.07. Gross margin improved to 90% from 86%, but adjusted EBITDA declined to $7.6 million as R&D and SG&A expenses increased. Quarterly operating cash flow was $5.7 million, and cash and investments ended June at $95.9 million with no debt. Delcath raised full-year 2026 revenue guidance to $104 million-$108 million and expects HEPZATO volume growth of at least 28%.
TradingKey
Thu, Aug 6
BlackRock TCP Capital Q2 2026 Earnings: Portfolio Sale Resets Leverage
BlackRock TCP Capital’s Q2 2026 earnings showed total investment income of approximately $40.0 million and GAAP net investment income of $18.1 million, or $0.22 per diluted share, versus $0.32 a year earlier. NAV ended the quarter at $6.58 per share. After quarter-end, TCPC agreed to sell 95% of a vehicle holding roughly $523 million of investments, a transaction expected to cut pro forma net leverage to about 0.4x but reduce NAV by approximately 10.4%, sharpening the trade-off between financial flexibility and book value.
TradingKey
Thu, Aug 6
Edgewise Q2 2026 Results: Higher R&D Spending Widens the Net Loss
Edgewise Therapeutics’ Q2 2026 results showed a net loss of $57.3 million, or $0.53 per share, versus $36.1 million and $0.34 a year earlier. R&D expense rose about 42% to $47.5 million as clinical development activity increased. Cash, cash equivalents and marketable securities totaled $460.7 million at June 30, excluding the $1.55 billion upfront proceeds received in July from Servier. The transaction shifts Edgewise to a cardiovascular-focused pipeline while providing funding for planned EDG-7500 and EDG-15400 trials.
TradingKey
Thu, Aug 6
Chegg Q2 2026 Earnings: Cost Cuts Support Cash Flow as Revenue Falls 51%
Chegg’s Q2 2026 revenue fell 51% year over year to $51.8 million, while GAAP net loss was $3.0 million. Cost reductions helped produce $9.1 million of adjusted EBITDA, a 17% margin, and $6.4 million of free cash flow despite restructuring payments. Chegg Skilling revenue rose 2% to $17.5 million but did not offset weakness elsewhere. For Q3, management guided to $43 million-$44 million of revenue, 48%-49% gross margin, and $1 million-$2 million of adjusted EBITDA as Chegg begins launching its employability platform.
TradingKey
Thu, Aug 6
Whitehawk Q2 2026 earnings: Cash runway extends into the second half of 2028
Whitehawk Therapeutics’ Q2 2026 results showed no revenue and a net loss of $16.6 million, narrower than $52.6 million a year earlier, as Q2 2025 included a $38.0 million upfront license fee. Diluted loss per share improved to $0.20 from $0.76. Cash, cash equivalents and short-term investments reached $190.0 million at June 30 after an $87.5 million private placement, supporting an expected runway into the second half of 2028. Whitehawk continued enrolling HWK-007 and HWK-016 and plans to start the HWK-206 Phase 1 study in Q3 2026.
TradingKey
Thu, Aug 6
FOX Fiscal Q4 2026 Earnings: World Cup Drives 28% Revenue Growth
Fox Corporation’s fiscal Q4 2026 revenue rose 28% to $4.21 billion, driven by the FIFA Men’s World Cup and continued Tubi-led digital advertising growth. Adjusted EBITDA increased 27% to $1.20 billion, and adjusted EPS climbed to $1.79 from $1.27. However, GAAP net income slipped to $696 million from $719 million as the prior-year quarter included a larger non-operating benefit. Television produced most of the profit growth, while Cable Network Programming EBITDA declined despite higher revenue. Full-year operating cash flow also fell as working capital absorbed cash.TradingKey
Thu, Aug 6
Sempra Q2 2026 Earnings: Profit Rises Despite Flat Revenue
Sempra’s Q2 2026 revenue was $2.997 billion, nearly unchanged from $3.000 billion a year earlier, while GAAP diluted EPS rose to $1.21 from $0.71 and adjusted EPS increased to $1.16 from $0.89. Higher equity earnings, lower tax expense, and gains across California, Texas, and Infrastructure supported profit growth, although interest expense increased. First-half operating cash flow reached $3.117 billion against more than $6 billion of capital spending. Sempra affirmed 2026 adjusted EPS guidance of $4.80 to $5.30 and its 7% to 9% long-term EPS growth target.
TradingKey
Thu, Aug 6
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Gains Over 1%, Philadelphia Semiconductor Index Rises Nearly 2%; Tech Stocks Strengthen, SpaceX Gains Nearly 8% Post-Earnings
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
Tesla Q3 Operating Profit Plunges 56% YoY, Dragged Down by Higher Operating Expenses Including R&D
